David Bunning, CEO of TLP Invest, speaker event

TAMID and BHC (Business Healthcare Club) are excited to host David Bunning, CEO of TLP Invest, a multi-asset class investment firm with a focus on disruptive technologies as well as investments in real estate, venture capital and private equity. Dave is a legend in the finance world, and has learned many lessons he will share with us. He is significantly involved in the healthcare industry.

Some background: Harvard Football, Head of Global Credit Trading at Citadel, Founder/CEO/CIO of TLP Invest

· When: Moday, December 5th at 3pm

· Where: University Hall 102

"I believe finance, when blended with a desire to improve humanity, can be a force for societal change. Since 2004, I’ve dedicated substantial energy to supporting efforts around developing effective treatments for life-threatening food allergies."

"I joined Citadel Investment Group LLC (Citadel) in 1991 when it was a startup hedge fund manager with less than $20 million in net assets under management. When I left Citadel in 2004 as Principal, Head of Global Credit Trading, and a member of the Management Committee, Citadel was managing net assets in excess of $10 billion."

"My work along with investments from TLP and SCF, often in partnership with others, has led to a number of innovative therapeutic developments including the first FDA approved food allergy therapy. Leveraging this experience, I also led TLP and SCF’s investment into other novel therapies, cancer treatments, and medical devices which are in various stages of FDA approval and commercialization."